CNSX:BE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Beleave Inc. operates as a medical cannabis company in Canada. More Details


Snowflake Analysis

Overvalued with worrying balance sheet.


Similar Companies

Share Price & News

How has Beleave's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: Insufficient data to determine BE's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine BE's volatility change over the past year.


Market Performance


7 Day Return

0%

BE

16.3%

CA Pharmaceuticals

2.7%

CA Market


1 Year Return

-87.5%

BE

21.2%

CA Pharmaceuticals

0.5%

CA Market

Return vs Industry: BE underperformed the Canadian Pharmaceuticals industry which returned -9.6% over the past year.

Return vs Market: BE underperformed the Canadian Market which returned -8.4% over the past year.


Shareholder returns

BEIndustryMarket
7 Day0%16.3%2.7%
30 Day0%35.0%12.3%
90 Day0%35.6%6.1%
1 Year-87.5%-87.5%21.2%21.2%4.2%0.5%
3 Year-97.8%-97.8%-25.4%-26.6%12.8%1.9%
5 Yearn/a290.6%287.5%49.7%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Beleave's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Beleave undervalued compared to its fair value and its price relative to the market?

0.49x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BE is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: BE is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BE is good value based on its PB Ratio (0.5x) compared to the CA Pharmaceuticals industry average (1.4x).


Next Steps

Future Growth

How is Beleave forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

60.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Beleave has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Beleave performed over the past 5 years?

-50.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BE is currently unprofitable.

Growing Profit Margin: BE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BE is unprofitable, and losses have increased over the past 5 years at a rate of 50.9% per year.

Accelerating Growth: Unable to compare BE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (35.9%).


Return on Equity

High ROE: BE has a negative Return on Equity (-312.52%), as it is currently unprofitable.


Next Steps

Financial Health

How is Beleave's financial position?


Financial Position Analysis

Short Term Liabilities: BE's short term assets (CA$2.7M) do not cover its short term liabilities (CA$16.9M).

Long Term Liabilities: BE's short term assets (CA$2.7M) exceed its long term liabilities (CA$1.2M).


Debt to Equity History and Analysis

Debt Level: BE's debt to equity ratio (213.7%) is considered high.

Reducing Debt: Insufficient data to determine if BE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if BE has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Beleave current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Bill Panagiotakopoulos (44 yo)

0.58

Tenure

CA$2,232,000

Compensation

Mr. Vasilios Panagiotakopoulos, also known as Bill, has been Chief Restructuring Officer at Beleave Inc. since June 2020. Mr. Panagiotakopoulos serves as Chief Executive officer at Beleave Inc. since April...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD177.48K).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Vasilios Panagiotakopoulos
CEO, COO0.58yrCA$2.23m1.16%
CA$ 32.2k
Roger Ferreira
Co-Founder & Chief Science Officerno dataCA$466.00kno data
Keith Li
Interim Chief Financial Officer0.58yrno datano data
Justin Kosalka
Director of Operationsno datano datano data
Myles Fontaine
VP of Sales2.33yrsno datano data
Dana Gidlow
Head of Veteran Affairs & Community Outreach4.42yrsno datano data

1.5yrs

Average Tenure

Experienced Management: BE's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Vasilios Panagiotakopoulos
CEO, COO0.58yrCA$2.23m1.16%
CA$ 32.2k
Andrew Steane
Independent Chairman of the Board & Member of Advisory Boardno datano data1.33%
CA$ 36.7k
Jeannette VanderMarel
Director1.08yrsno data4.22%
CA$ 116.9k
Kevin Keagan
Director1.75yrsCA$668.65k2.21%
CA$ 61.3k

1.8yrs

Average Tenure

Experienced Board: BE's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.


Top Shareholders

Company Information

Beleave Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Beleave Inc.
  • Ticker: BE
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$2.769m
  • Shares outstanding: 553.87m
  • Website: https://beleave.com

Location

  • Beleave Inc.
  • 2030 Bristol Circle
  • Suite 115
  • Oakville
  • Ontario
  • L6H 0H2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BECNSX (Canadian National Stock Exchange)YesNew Common SharesCACADDec 2015
4B9DB (Deutsche Boerse AG)YesNew Common SharesDEEURDec 2015
BLEV.FOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDDec 2015

Biography

Beleave Inc. operates as a medical cannabis company in Canada. The company cultivates and sells medical and recreational cannabis products. It also operates a network of medical cannabis clinics in Ontario...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/03 01:09
End of Day Share Price2020/08/06 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.